IP Library Granted Patent US 8,206,925
Granted Patent B2
US 8,206,925 · App. 12/386,146 · Granted Jun 26, 2012

Splice variants of human IL-23 receptor (IL-23R) mRNA and use of a delta 9 isoform in predicting inflammatory bowel diseases

Assignee: Medical Diagnostic Laboratories, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,206,925
App. No.
12/386,146
Filed
Apr 14, 2009
Granted
Jun 26, 2012
Kind
B2
Art Unit
1682
USPC
435/6.12
Abstract

There is disclosed the cloning and identification of human IL-23R splice variants caused by alternative splicing of the IL-23R mRNA in human. Alternative mRNA forms occur through skipping one, multiple full exons or partial exons, within the IL-23R gene. A total of twenty-five (25) different IL-23R transcripts were identified. A novel exon deletion (exon 9) isoform in the interleukin 23 receptor is disclosed, denoted as Δ9. The present application also describes a quantitative assay to measure different IL-23R isoform. Detection of Δ9 isoform of IL-23R is predominantly present in colon and cervical tissues. A decrease in Δ9 is observed in inflamed colon tissues in Crohn's patients. There is disclosed a method of predicting Crohn's disease by measuring Δ9 isoform of IL-23R.

Claims (5)

1. A method of determining the quantitative level of a Δ9 isoform of IL-23R having the sequence consisting of SEQ ID NO: 6, comprising the steps of: (a) obtaining a biological sample; (b) performing quantitative PCR on said biological sample; and (c) determining the quantitative level of the Δ9 isoform of IL-23R having the sequence consisting of SEQ ID NO: 6 in said biological sample based on said quantitative PCR.

2. The method of claim 1 , wherein said biological sample is a cell, tissue, or biological fluid.

3. The method of claim 2 , wherein said tissue is colon tissue.

4. The method of claim 2 , wherein said biological fluid is whole blood.

5. The method of claim 1 , wherein said step (b) is performed using a forward primer and a reverse primer, said forward primer having a nucleotide sequence set forth in SEQ ID NO: 31, and said reverse primer having a nucleotide sequence set forth in SEQ ID NO: 32.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
Continuity (5)
Provisional Application 61124092 · Apr 14, 2008
Provisional Application 61124099 · Apr 14, 2008
Provisional Application 61124367 · Apr 14, 2008
Provisional Application 61124355 · Apr 16, 2008
Related Publication 20090311694A1 · Dec 17, 2009